Filing Flows › Nuo Therapeutics (AURX) › Q3 2025
Nuo Therapeutics (AURX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 30, 2025
Nuo Therapeutics (AURX) reported revenue of $1.0M for the third quarter 2025 (Q3 2025), +178% from a year earlier and +47% from the quarter before. Operating margin was -52.3%, net loss $538K (52.1% of revenue).
Nuo Therapeutics, Q3 2025: revenue $1.0M (+178% year over year), operating margin -52.3%, net loss $538K, operating cash flow −$707K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | +47% | +178% |
| Operating profit | −$540K | — | — |
| Net earnings | −$538K | — | — |
| Operating cash flow | −$707K | -369% | — |
What changed
Revenue was $1.0M in Q3 2025, up 178% year over year and up 47% from the previous quarter. Product was the largest line at 93% of revenue. Product added $586K year over year (up 158%), 89% of the total change.
Gross margin was 60.6%, down 12.3 points from a year earlier. Operating costs exceeded revenue by $540K, an operating margin of -52.3%. Operating expenses grew 37% against revenue growth of 178%. The quarter ended with a net loss of $538K, narrower than the previous quarter's $650K loss.
Operating cash flow was −$707K. Non-cash charges added back $23K of depreciation and $20K of share-based compensation. Working capital and other items used $212K.
Questions
What was Nuo Therapeutics' revenue in the third quarter 2025?
Nuo Therapeutics (AURX) reported revenue of $1.0M for the third quarter 2025 (Q3 2025), +178% from a year earlier and +47% from the quarter before.
Was Nuo Therapeutics profitable in the third quarter 2025?
Operating loss was $540K (-52.3% of revenue) and net loss $538K.
Source: Nuo Therapeutics 10-Q on SEC EDGAR.